Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management
Luigi Roffi, Guido Colloredo Mels, Guido Antonelli, Giorgio Bellati, Fabio Panizzuti, Alberto Piperno, Massimo Pozzi, Davide Ravizza, Giovanni Angeli, Ferdinando Dianzani, Giuseppe Mancia – 1 March 1995 – Recombinant interferon alfa (r‐IFNα2) has been shown to normalize the aminotransferase levels in approximately 50% of patients with chronic hepatitis C virus (HCV). Few patients experience a relapse during the treatment, in spite of a complete initial response (breakthrough). We studied 191 HCV Ab‐positive patients with histologically proven chronic hepatitis.